Benjamin Edwards Inc. Takes Position in Illumina, Inc. (NASDAQ:ILMN)

Benjamin Edwards Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,053 shares of the life sciences company's stock, valued at approximately $541,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. BNP Paribas acquired a new stake in shares of Illumina during the fourth quarter worth about $302,000. BNP Paribas Financial Markets grew its stake in Illumina by 100.5% in the fourth quarter. BNP Paribas Financial Markets now owns 590,287 shares of the life sciences company's stock valued at $78,880,000 after purchasing an additional 295,896 shares in the last quarter. Arohi Asset Management PTE Ltd. lifted its position in shares of Illumina by 91.9% in the fourth quarter. Arohi Asset Management PTE Ltd. now owns 121,270 shares of the life sciences company's stock valued at $16,205,000 after buying an additional 58,070 shares during the last quarter. Keel Point LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $204,000. Finally, Ion Asset Management Ltd. lifted its position in shares of Illumina by 10.9% in the fourth quarter. Ion Asset Management Ltd. now owns 800,500 shares of the life sciences company's stock valued at $106,971,000 after buying an additional 79,001 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ILMN shares. Barclays cut their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Stephens restated an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Citigroup reduced their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Finally, Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and a consensus target price of $130.95.

Illumina Price Performance

Shares of Illumina stock traded up $5.81 during trading on Monday, reaching $81.57. 3,153,675 shares of the company's stock were exchanged, compared to its average volume of 2,290,791. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a market cap of $12.91 billion, a P/E ratio of -10.62, a PEG ratio of 1.60 and a beta of 1.35. The firm's 50-day moving average price is $78.85 and its 200 day moving average price is $112.70.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Illumina's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.